Publication Name	World Journal of Gastroenterology
Manuscript ID	3449
Country	China

Received	2013-05-01 12:59
Peer-Review Started	2013-05-03 10:33
To Make the First Decision	2013-05-14 18:36
Return for Revision	2013-05-19 18:14
Revised	2013-06-05 06:06
Second Decision	2013-07-31 14:35
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-08-01 05:21
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-08-13 12:56
Typeset the Manuscript	2013-08-21 11:17
Publish the Manuscript Online	2013-09-09 09:30

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Case Report
Article Title	Lactic acidosis during telbivudine treatment for HBV: A case report and literature review
Manuscript Source	Invited Manuscript
All Author List	Jia-Lin Jin, Piao Hu, Jia-Hong Lu, Su-Shan Luo, Xiao-Yun Huang, Xin-Hua Weng and Ji-Ming Zhang
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 81071354 National Natural Science Foundation of China 81271833 National “973’’ Project 2012CB519001 National Science and Technology Major Project of China 2012ZX10002007-001-002 National Science and Technology Major Project of China 2013ZX10002001
Corresponding Author	Ji-Ming Zhang, MD, Department of Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhonglu, Jing'an District, Shanghai 200040, China. jmzhang@fudan.edu.cn
Key Words	Lactic acidosis/hyperlactatemia; Telbivudine; Hepatitis B virus; Nucleoside analogue; Adverse effects
Core Tip	Myopathy is the most common side effect resulting from telbivudine. Lactic acidosis (LA) is rare but fatal, and LA caused by telbivudine has never been reported. Here, we report the first case of chronic hepatitis B developing severe refractory LA during telbivudine monotherapy. This case shows that telbivudine may cause muscle damage and even lead to fatal LA in chronic hepatitis B patients. Patients under telbivudine treatment should be closely monitored for muscular, blood lactate and other mitochondrial toxicity associated side effects.
Publish Date	2013-09-09 09:30
Citation	Jin JL, Hu P, Lu JH, Luo SS, Huang XY, Weng XH, Zhang JM. Lactic acidosis during telbivudine treatment for HBV: A case report and literature review. World J Gastroenterol 2013; 19(33): 5575-5580
URL	http://www.wjgnet.com/1007-9327/full/v19/i33/5575.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i33.5575

Full Article (PDF)	WJG-19-5575.pdf
Manuscript File	3449-Review.doc
Answering Reviewers	3449-Answering reviewers.pdf
Copyright License Agreement	3449-Copyright assignment.pdf
Peer-review Report	3449-Peer review(s).pdf
Scientific Editor Work List	3449-Scientific editor work list.doc